
FDA Grants Fast Track Designation to Emactuzumab for Unresectable TGCT
The FDA has granted fast track designation to the CSF-1R–inhibiting monoclonal antibody emactuzumab for the treatment of patients with tenosynovial giant cell tumor (TGCT) who are not amenable to or who would not benefit from surgery.1 Previously reported …